A federal judge in Trenton, New Jersey, has denied class certification in a suit by users of a drug made by Ranbaxy Pharmaceuticals that contained bits of broken glass.

The suit was brought on behalf of a potential class of consumers who may have purchased tainted Atorvastatin pills and want their money back. Certification was denied because figuring out which consumers were sold the contaminated pills would require conducting a minitrial for each plaintiff, U.S. District Judge Peter Sheridan said Nov. 13 in Fenwick v. Ranbaxy.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]